Study of Ablation for the Pulmonary Focal Pure Ground Glass Opacity (pGGO) (pGGO)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01429649 |
Recruitment Status : Unknown
Verified September 2011 by Chen Weisheng, Dongfang Hospital Beijing University of Chinese Medicine.
Recruitment status was: Recruiting
First Posted : September 7, 2011
Last Update Posted : September 7, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
With the advent of CT screening for lung cancer, there is an increase in the detection of pulmonary lesions with focal pure ground-glass opacity (pGGO). The pure Ground-glass opacities can be caused by normal expiration, partial filling of air spaces, partial collapse of alveoli, interstitial thickening, inflammation, oedema, fibrosis, and lepidic proliferation of neoplasm. Precise details of the natural history of focal pure GGO are still largely unclear. A number of differential diagnoses are possible, including inflammatory disease, focal scar, atypical adenomatous hyperplasia (AAH), and adenocarcinoma in situ. Some of pGGOs remained stable over a considerable time. A long doubling time for pGGOs is already known. Therefore, the strategy of treatment for focal pure GGO lesions is still undecided. The major issue is whether or not the doctors should treat these patients at all or wait until the first sign of a solid lesion developes which may take many years.
The purpose of this study is to determine if the ablation therapy is safe and effective for the pulmonary pGGO.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pulmonary Lesions | Procedure: cryotherapy or radiofrequency ablation | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Prospective Study of Ablation of Pulmonary Focal Pure Ground Glass Opacity |
Study Start Date : | September 2011 |
Estimated Primary Completion Date : | October 2014 |
Estimated Study Completion Date : | December 2014 |
Arm | Intervention/treatment |
---|---|
Experimental: ablation
Cryoablation or Radiofrequency ablation for the pGGO
|
Procedure: cryotherapy or radiofrequency ablation
Cryoablation or Radiofrequency ablation is performed under CT image guidance. |
No Intervention: Follow up CT scann
The patients will receive follow up with CT scan every 6-9 months.
|
- The changing of the lesion [ Time Frame: 3 years ]
To determine the efficacy rate of CT image guided ablation for pulmonary focal pGGO.
To determine the feasibility and safety of CT image guided ablation in patients with pulmonary pGGO.
- The side effect of the therapy. [ Time Frame: 3 years ]Intra and post-operative complications rates. Quality-of-life assessment

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- The lesion(s) treated with ablation must be =< 2.0 cm in greatest dimension
- All patients are required to have been evaluated in a multi-disciplinary tumor conference to ensure that the lesion is suitable for Image-guided percutaneous ablation
- Platelet count ≥ 100 x 109/L
- International normalized ratio (INR) < 1.5
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- A signed study specific consent form is required
Exclusion Criteria:
- Direct evidence of regional or distant metastases,or synchronous primary or prior malignancy in the past 5 years
- Unable to lie flat or has respiratory distress at rest
- Uncontrolled coagulopathy or bleeding disorders
- Evidence of active systemic, pulmonary, or pericardial infection
- Women who are pregnant or breastfeeding
- Patients with poor pulmonary function

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01429649
Contact: Weisheng Chen, MD | +8618960826090 | weishengmd@hotmail.com |
China, Fujian | |
Dongfang Hospital | Recruiting |
Fuzhou, Fujian, China, 350025 | |
Contact: Yonggang Liang +8659122859888 ext 59388 war_ren@163.com |
Principal Investigator: | Weisheng Chen, MD | Dongfang Hospital Beijing University of Chinese Medicine |
Responsible Party: | Chen Weisheng, The vice chief of the Thoracic Division, Dongfang Hospital Beijing University of Chinese Medicine |
ClinicalTrials.gov Identifier: | NCT01429649 History of Changes |
Other Study ID Numbers: |
kj2011001 |
First Posted: | September 7, 2011 Key Record Dates |
Last Update Posted: | September 7, 2011 |
Last Verified: | September 2011 |
pure pulmonary ground glass opacity |
Methamphetamine Central Nervous System Stimulants Physiological Effects of Drugs Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Dopamine Agents |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Adrenergic Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Dopamine Uptake Inhibitors |